Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

[1]  K. Blennow,et al.  C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease , 2015, Alzheimer's & Dementia.

[2]  W. M. van der Flier,et al.  Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. , 2015, JAMA neurology.

[3]  K. Blennow,et al.  Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease , 2015, Alzheimer's & Dementia.

[4]  J. Godbout,et al.  Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease , 2015, Neuropharmacology.

[5]  J. Kassubek,et al.  Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? , 2015, International journal of molecular sciences.

[6]  K. Blennow,et al.  Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls , 2015, Alzheimer's Research & Therapy.

[7]  Frederick A Schmitt,et al.  Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[8]  K. Blennow,et al.  Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease , 2014, Dementia and Geriatric Cognitive Disorders Extra.

[9]  C. Franceschi,et al.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  K. Blennow,et al.  CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment , 2014, Journal of Neuroimmunology.

[11]  S. Engelborghs,et al.  Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.

[12]  P. Mcgeer,et al.  The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy , 2013, Acta Neuropathologica.

[13]  A. Mandal,et al.  Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling. , 2013, Cellular signalling.

[14]  V. Perry,et al.  Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration , 2013, Seminars in Immunopathology.

[15]  K. Blennow,et al.  Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. , 2012, Journal of Alzheimer's disease : JAD.

[16]  K. Blennow,et al.  Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility , 2011, NeuroMolecular Medicine.

[17]  W. Klein,et al.  Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease , 2011, Cellular and Molecular Neurobiology.

[18]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  K. Blennow,et al.  Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease , 2010, Brain Research.

[21]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[22]  B. Winblad,et al.  Lack of Accuracy for the Proposed ‘Dubois Criteria’ in Alzheimer’s Disease: A Validation Study from the Swedish Brain Power Initiative , 2010, Dementia and Geriatric Cognitive Disorders.

[23]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[24]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[25]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[26]  P. Reddy,et al.  Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease , 2009, Experimental Neurology.

[27]  M. Block,et al.  NADPH oxidase as a therapeutic target in Alzheimer's disease , 2008, BMC Neuroscience.

[28]  T. Town,et al.  Inflammaging as a prodrome to Alzheimer's disease , 2008, Journal of Neuroinflammation.

[29]  Brian J. Bacskai,et al.  Aβ Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks , 2008, Neuron.

[30]  J. Mellors,et al.  YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. , 2008, The American journal of pathology.

[31]  M. Sceniak,et al.  Slow GABAA mediated synaptic transmission in rat visual cortex , 2008, BMC Neuroscience.

[32]  E. Todeva.  Networks , 2007 .

[33]  M. Mattson,et al.  Calcium and neurodegeneration , 2007, Aging cell.

[34]  F. Schmitt,et al.  Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment , 2007, Neurology.

[35]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[36]  G. Castellani,et al.  Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans , 2007, Mechanisms of Ageing and Development.

[37]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[38]  J. Bernal,et al.  RC3/neurogranin is expressed in pyramidal neurons of motor and somatosensory cortex in normal and denervated monkeys , 2005, The Journal of comparative neurology.

[39]  M. Frotscher,et al.  Neurogranin is expressed by principal cells but not interneurons in the rodent and monkey neocortex and hippocampus , 2004, The Journal of comparative neurology.

[40]  L. Schwarzfischer,et al.  Transcriptional Regulation of CHI3L1, a Marker Gene for Late Stages of Macrophage Differentiation* , 2003, Journal of Biological Chemistry.

[41]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[42]  E. Masliah,et al.  Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease , 2001, Neurology.

[43]  K. Blennow,et al.  Identification of synaptic vesicle, pre‐ and postsynaptic proteins in human cerebrospinal fluid using liquid‐phase isoelectric focusing , 1999, Electrophoresis.

[44]  K. Blennow,et al.  Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease , 1998, International Psychogeriatrics.

[45]  Julia W. Chang,et al.  Dendritic Translocation of RC3/Neurogranin mRNA in Normal Aging, Alzheimer Disease and Fronto‐Temporal Dementia , 1997, Journal of neuropathology and experimental neurology.

[46]  Brian,et al.  Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. , 1993, The Journal of biological chemistry.

[47]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[48]  Y. Ben-Ari,et al.  Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  J. Molinuevo,et al.  Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[50]  Claudio Babiloni,et al.  Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. , 2011, Journal of Alzheimer's disease : JAD.

[51]  F. Schmitt,et al.  Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[52]  K. Blennow,et al.  Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele , 2005, Journal of Neural Transmission.

[53]  H. Braak,et al.  Neuropathology of Alzheimer’s Disease , 2004 .